Gilead Sciences, Inc. GILD
What this company does
Written from the business description in GILEAD SCIENCES, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 24 February 2026. Every sentence was checked against that document before publication.
Revenue compounded at +3.6% a year over five years — but profit grew faster: net income at +133.3%, earnings per share at +132.4%.
The share count fell from 1.25B to 1.24B — the buyback concentrates the same profit into fewer slices.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Each USD of equity produced 40 cents of profit this year.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 29.4 | 28.8 | 27.1 | 27.3 | 27.3 | 24.7 | 22.4 | 22.1 | 26.1 | 30.4 | 32.6 | 24.9 | 11.2 | 9.7 | 8.4 | 7.9 | 7.0 | 5.3 | 4.2 |
| Operating income $B | 10.0 | 1.7 | 7.6 | 7.3 | 9.9 | 4.1 | 4.3 | 8.2 | 14.1 | 17.6 | 22.2 | 15.3 | 4.5 | 4.0 | 3.8 | 4.0 | 3.5 | 2.7 | 2.2 |
| EBITDA $B | 10.4 | 2.0 | 8.0 | 7.7 | 10.2 | 4.4 | 4.5 | 8.4 | 14.4 | 17.8 | 22.4 | 15.4 | 4.6 | 4.1 | 3.9 | 4.0 | 3.6 | 2.7 | 2.2 |
| Income tax $B | 1.3 | 0.2 | 1.2 | 1.2 | 2.1 | 1.6 | −0.2 | 2.3 | 8.9 | 3.6 | 3.6 | 2.8 | 1.2 | 1.0 | 0.9 | 1.0 | 0.9 | 0.7 | 0.6 |
| Net income $B | 8.5 | 0.5 | 5.7 | 4.6 | 6.2 | 0.1 | 5.4 | 5.5 | 4.6 | 13.5 | 18.1 | 12.1 | 3.1 | 2.6 | 2.8 | 2.9 | 2.6 | 2.0 | 1.6 |
| Free cash flow $B | 9.5 | 10.3 | 7.4 | 8.3 | 10.8 | 7.5 | 8.3 | 7.5 | 11.3 | 16.3 | 20.5 | 12.3 | 2.9 | 2.8 | 3.5 | 2.8 | 2.8 | 2.0 | 1.6 |
| EPS, diluted $ | 6.78 | 0.38 | 4.50 | 3.64 | 4.93 | 0.10 | 4.22 | 4.17 | 3.51 | 9.94 | 11.91 | 7.35 | 1.81 | 1.64 | 1.77 | 1.66 | 2.82 | 2.06 | 1.64 |
| Dividend / sh $ | 3.16 | 3.08 | 3.00 | 2.92 | 2.84 | 2.72 | 2.52 | 2.28 | 2.08 | 1.84 | 1.29 | 0.00 | 0.00 | · | · | · | · | · | · |
| Payout % | 47 | 816 | 67 | 81 | 58 | 2804 | 60 | 54 | 59 | 18 | 10 | 0 | 0 | · | · | · | · | · | · |
| ROE % | 40.5 | 2.3 | 25.7 | 21.7 | 31.7 | 0.6 | 24.5 | 26.1 | 23.5 | 72.2 | 106.6 | 90.3 | 29.7 | 32.3 | 44.5 | 47.4 | 49.5 | 46.3 | · |
| Shares out B | 1.24 | 1.25 | 1.25 | 1.25 | 1.25 | 1.25 | 1.27 | 1.28 | 1.31 | 1.31 | 1.42 | 1.50 | 1.53 | 1.52 | 0.75 | 0.80 | 0.90 | 0.91 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
This company against its peers
Reconciled in 19 of 19 fiscal years. 2 checks could not be computed.